Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 4041Question →

A 35-year-old woman comes to the primary care clinic for a routine follow-up visit. Two months ago, she was diagnosed with an unprovoked deep vein thrombosis of the right lower extremity and was appropriately started on rivaroxaban. She has no other medical conditions and takes no other medications. During the interview, she appears visibly distressed and states, "I have been feeling very down and overwhelmed since my diagnosis, so I plan to start taking an over-the-counter St. John's wort supplement to improve my mood. Additionally, my aunt told me that because I am on a strong blood thinner, I need a screening head MRI to check for hidden bleeding, and she said I should start getting annual mammograms immediately to be safe." Which of the following is the most appropriate initial counseling response by the physician?

Show answer & explanation

Answer: It is understandable to feel overwhelmed, but St. John's wort can decrease the effectiveness of your blood thinner; furthermore, a screening head MRI and mammography are not indicated for you at this time.

Answer

The most appropriate response empathetically validates the patient's emotional distress while correctly educating her on the drug-herbal interaction (St. John's wort decreases rivaroxaban efficacy) and accurately applying preventive and diagnostic guidelines (no indication for screening head MRI or mammography at age 35).
This response represents the best initial communication strategy because it first validates the patient's emotional distress, which builds rapport and trust. It then clearly and accurately educates the patient about a severe pharmacokinetic interaction: St. John's wort is a well-known, potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Because rivaroxaban is cleared via these pathways, coadministration would significantly decrease its plasma concentration, putting the patient at high risk for a recurrent thromboembolism. Finally, the response correctly educates the patient that she does not meet the criteria for screening mammography (which typically begins at age 40 according to USPSTF guidelines) and that routine head imaging is never indicated to screen for bleeding in asymptomatic patients on anticoagulants.

Step-by-Step Solution

1
Evaluate the physician's communication approach.
The physician must validate the patient's feelings of being overwhelmed rather than dismissing them or acting paternalistically.
Establishing empathy and a strong therapeutic alliance is essential before correcting patient misconceptions or refusing requested tests.
2
Assess the pharmacologic safety of St. John's wort in this patient.
Identify that St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein.
Rivaroxaban is metabolized by CYP3A4 and is a P-gp substrate; induction of these pathways will lower its plasma concentration and significantly increase the risk of recurrent DVT.
3
Evaluate the need for the requested screening tests (head MRI and mammogram).
Determine that routine head MRIs are not indicated for asymptomatic patients on anticoagulation, and screening mammography is generally initiated at age 40 for average-risk women.
Performing unnecessary tests increases healthcare costs, patient anxiety, and the risk of false-positive cascades.

Key Concept

Effective patient counseling involves empathetic validation of concerns combined with accurate education regarding dangerous pharmacokinetic interactions (e.g., St. John's wort inducing CYP3A4/P-gp) and strict adherence to evidence-based preventive screening guidelines.
Question 4042Question →

An oncology research network is preparing to launch a randomized, placebo-controlled trial evaluating a new monoclonal antibody for the prevention of disease recurrence in high-risk melanoma patients. The trial is originally powered at 80%80\% to detect a hazard ratio of 0.700.70 with a two-sided α\alpha level of 0.050.05. Prior to patient enrollment, the data and safety monitoring board (DSMB) reviews recent post-marketing surveillance data from a similar drug class that revealed rare but fatal autoimmune toxicities. Consequently, the DSMB mandates that the study must use a more stringent two-sided α\alpha level of 0.010.01 to minimize the risk of a false-positive efficacy finding. Due to an absolute cap on available grant funding, the investigators are unable to increase the total number of enrolled patients or extend the follow-up duration. Which of the following is the most likely statistical consequence of implementing the DSMB's mandate under these constraints?

Show answer & explanation

Answer: The trial's statistical power will fall below 80%, increasing the probability of a Type II error.

Answer

The trial's statistical power will fall below 80%, increasing the probability of a Type II error.
In statistical hypothesis testing, the power of a study (the probability of correctly rejecting a false null hypothesis) is determined by the α\alpha level, the sample size, and the true effect size. The α\alpha level (Type I error rate) and β\beta level (Type II error rate) are inversely related for any given sample size and effect size. By lowering the α\alpha level from 0.050.05 to 0.010.01, the researchers require a higher burden of statistical proof to declare significance. Because the sample size is fixed due to absolute funding constraints and the true effect size is assumed constant, this stricter significance threshold directly increases β\beta, the probability of failing to detect a true difference (a Type II error). Consequently, the statistical power, calculated as 1−β1 - \beta, will fall below the originally planned 80%80\%.

Step-by-Step Solution

1
Identify the relationship between alpha, beta, and sample size.
Alpha (Type I error rate) and beta (Type II error rate) are inversely related when sample size and effect size are held constant.
A stricter alpha shifts the critical value, requiring a larger observed effect to reject the null hypothesis.
2
Determine the effect of the DSMB mandate on the alpha level.
The alpha level is reduced from 0.05 to 0.01, making the criteria for statistical significance more stringent.
The DSMB wants to reduce the chance of a false positive due to the severe side effect profile.
3
Evaluate the impact of the fixed constraints.
Because funding is capped, sample size and follow-up time cannot be increased to compensate for the stricter alpha.
Without a larger sample size to improve precision, the inverse relationship between alpha and beta is unavoidable.
4
Conclude the final statistical consequence.
Beta increases, meaning power (1 - beta) must decrease below the originally planned 80%.
The increased stringency increases the likelihood of failing to detect a true clinical benefit.

Key Concept

The inverse relationship between Type I error (alpha) and Type II error (beta) given a fixed sample size and effect size.
Question 4043Question →

A 58-year-old woman with a history of recurrent major depressive disorder and newly diagnosed nonvalvular atrial fibrillation presents to the clinic for a follow-up visit. She is currently taking citalopram. At her last visit, apixaban was prescribed for stroke prophylaxis. Today, she informs the physician, "I threw that prescription away. I don't want to take synthetic chemicals. I have decided to manage my heart condition naturally with St. John's wort and a daily aspirin instead." The patient is alert, oriented, and correctly states that not taking apixaban increases her risk of an ischemic stroke, but she says she accepts this risk. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Explore the patient's underlying fears regarding synthetic medications and clarify her understanding of her proposed regimen.

Answer

The most appropriate next step is to explore the patient's underlying fears regarding synthetic medications and clarify her understanding of her proposed regimen.
The correct answer focuses on exploring the patient's fears and beliefs. In the context of patient counseling and health education, a patient's refusal of standard-of-care therapy should be met with curiosity rather than confrontation or immediate acceptance. By using open-ended questions to explore her specific aversion to 'synthetic chemicals' and her understanding of her alternative regimen, the physician builds trust. This therapeutic alliance is necessary before any effective health education regarding the inadequacy of aspirin for her condition, or the risks of her alternative plan, can be received by the patient.

Step-by-Step Solution

1
Assess the patient's clinical decision-making capacity.
The patient clearly understands her diagnosis, the proposed treatment, and the risks of refusing treatment (stroke), indicating intact capacity.
Before proceeding with counseling or ethical interventions, the physician must establish that the patient is capable of making her own medical decisions.
2
Evaluate the patient's alternative treatment plan.
The patient wants to use St. John's wort and aspirin. This is medically insufficient for AFib stroke prophylaxis and poses a drug-interaction risk (serotonin syndrome) with her citalopram.
Understanding the flaws in the patient's self-directed care plan helps guide the educational focus of the conversation.
3
Determine the best communication strategy.
Employ active listening and open-ended questions to explore her aversion to 'synthetic chemicals'.
Directly challenging the patient, overriding her autonomy, or ignoring the issue damages the patient-physician relationship. Exploring her specific fears allows the physician to provide targeted, empathetic health education.

Key Concept

When a patient with decision-making capacity refuses recommended treatment, the most appropriate initial step is to use patient-centered counseling skills to explore their underlying beliefs, fears, and rationale without judgment.
Estimated Time:1m 30s
Question 4044Question →

A 58-year-old cisgender male presents to the clinic to establish care. He reports feeling well and has no acute symptoms. His past medical history is notable for HIV infection, diagnosed 10 years ago, and essential hypertension. He is currently maintained on a daily antiretroviral regimen of bictegravir, emtricitabine, and tenofovir alafenamide, with a most recent CD4 count of 520 cells/mm³ and an undetectable viral load. He has a 30-pack-year smoking history but successfully quit 5 years ago. His last preventive health visit was 3 years ago, during which he underwent a screening colonoscopy with normal findings. His vaccination records confirm receipt of a Tdap booster 3 years ago and an inactivated influenza vaccine 2 weeks ago. He has never received any pneumococcal or herpes zoster vaccines. Vital signs and physical examination today are unremarkable.

Which of the following preventive interventions are currently indicated for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Low-dose chest computed tomography; 20-valent pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine

Answer

The indicated preventive interventions for this patient are low-dose chest computed tomography (LDCT), the 20-valent pneumococcal conjugate vaccine (PCV20), and the recombinant zoster vaccine.
The correct selections represent three distinct guideline-concordant interventions for this patient. First, annual low-dose chest computed tomography is recommended by the USPSTF for adults aged 50 to 80 years with a minimum 20 pack-year smoking history who currently smoke or have quit within the past 15 years. This patient is 58, has a 30 pack-year history, and quit 5 years ago, perfectly meeting the criteria. Second, the Advisory Committee on Immunization Practices (ACIP) recommends that adults aged 19 to 64 years with specific underlying conditions (including HIV) who have not previously received a pneumococcal conjugate vaccine receive either a single dose of PCV20 or a dose of PCV15 followed by a dose of PPSV23. Thus, PCV20 is fully indicated. Finally, the recombinant zoster vaccine is recommended as a 2-dose series for all adults aged 50 and older, as well as for those 19 and older who are immunocompromised. Since this patient is both 58 and has HIV, he has dual indications for this vaccine.

Step-by-Step Solution

1
Evaluate the patient's age and smoking history for cancer screening indications.
The patient is 58 years old, has a 30 pack-year history, and quit 5 years ago.
The USPSTF recommends annual LDCT for lung cancer screening in adults aged 50 to 80 with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years.
2
Assess immunization needs based on age and comorbid conditions (HIV).
The patient requires protection against pneumococcal disease and herpes zoster.
HIV is an immunocompromising condition that necessitates specific adult vaccinations, and his age (58) provides additional indications for certain vaccines.
3
Determine the correct pneumococcal vaccination sequence for a vaccine-naive adult with HIV.
The patient should receive either PCV20 alone or PCV15 followed by PPSV23.
ACIP guidelines dictate that higher-valent conjugate vaccines should be used as the primary dose for naive adults with high-risk conditions, making PPSV23 alone incorrect.
4
Evaluate indications for abdominal aortic aneurysm (AAA) screening.
AAA screening is not currently indicated.
Although the patient is a male with a history of smoking, the USPSTF age criteria for a one-time screening ultrasound is 65 to 75 years; this patient is 58.

Key Concept

Complex preventive care requires synthesizing age-based screening guidelines with disease-specific immunization protocols, particularly in patients with immunocompromising conditions like HIV.
Question 4045Question →

A 54-year-old man admitted for sepsis has blood cultures drawn in the emergency department. The cultures grow methicillin-resistant Staphylococcus aureus (MRSA) at 24 hours, but this critical result is not communicated to the primary ward team for another 48 hours. The delay leads to progression of his infection and transfer to the intensive care unit. The hospital's quality improvement committee decides to conduct a Root Cause Analysis (RCA) regarding this delayed reporting event. Arrange the following steps of the RCA process in the correct chronological order as they should be performed by the committee.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with forming a multidisciplinary team, followed by mapping the timeline of events, analyzing contributing factors with a fishbone diagram, implementing a corrective action plan, and finally measuring the outcomes.
Root Cause Analysis (RCA) is a structured, retrospective methodology used to investigate adverse events. The standard Joint Commission framework dictates a specific sequence: First, a multidisciplinary team is chartered (as frontline perspectives are critical). Second, the team gathers data to establish a detailed timeline of events. Third, the team analyzes this timeline using tools like the Ishikawa (fishbone) diagram to identify system vulnerabilities and root causes. Fourth, an action plan is formulated and implemented to address these root causes. Finally, outcome metrics are tracked to ensure the intervention prevents future occurrences.

Step-by-Step Solution

1
Identify the proper quality improvement methodology.
RCA is selected because it is a retrospective approach used after an adverse event or near miss.
To investigate the underlying causes of a specific incident.
2
Determine the first phase of the RCA framework.
Form a multidisciplinary team.
Frontline workers involved in the event are essential to accurately understand the process.
3
Determine the data gathering phase.
Construct a chronological timeline.
The team must understand exactly what happened before they can analyze why it happened.
4
Determine the analysis phase.
Use an Ishikawa diagram to identify contributing factors.
To move beyond human error and identify system-level vulnerabilities.
5
Determine the intervention phase.
Design and implement a corrective action plan.
To mitigate the identified root causes.
6
Determine the follow-up phase.
Establish metrics to measure effectiveness.
To ensure the intervention actually improves safety and does not introduce new errors.

Key Concept

Root Cause Analysis (RCA) implementation sequence
Estimated Time:1m 30s
Question 4046Question →

A 62-year-old woman is evaluated at home by a hospice physician for severe abdominal pain and vomiting. She has widely metastatic ovarian cancer complicated by extensive peritoneal carcinomatosis. Two weeks ago, she transitioned to home hospice care with the explicit goal of maximizing comfort. She strongly refuses any hospitalizations, surgical interventions, or invasive procedures, including nasogastric intubation.

For the past 48 hours, she has had worsening colicky abdominal pain, significant nausea, and multiple episodes of large-volume, bilious emesis. Her last bowel movement was four days ago. Her current medications include a continuous subcutaneous morphine infusion for baseline pain control.

Vital signs show a heart rate of 110/min and a blood pressure of 90/60 mmHg. Physical examination reveals a visibly distended abdomen that is tympanic to percussion. Bowel sounds are high-pitched and tinkling. The physician diagnoses a malignant mechanical bowel obstruction.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Administer subcutaneous octreotide

Answer

Administer subcutaneous octreotide
Malignant bowel obstruction (MBO) is a common, distressing complication of advanced abdominal and pelvic malignancies, particularly ovarian cancer. In patients with terminal illness who refuse or are not candidates for surgical decompression or nasogastric (NG) tube placement, symptom management is the primary goal. Subcutaneous octreotide, a somatostatin analog, is highly effective for MBO in the hospice setting. It inhibits the secretion of gastric, pancreatic, and intestinal fluids and decreases splanchnic blood flow. This rapidly reduces intraluminal volume, thereby relieving bowel distension, colicky abdominal pain, nausea, and vomiting without the need for invasive mechanical decompression.

Step-by-Step Solution

1
Identify the primary clinical diagnosis.
The patient is experiencing a malignant mechanical bowel obstruction (MBO) due to peritoneal carcinomatosis from ovarian cancer.
The symptoms of colicky pain, large-volume bilious emesis, lack of stool, and a distended, tympanic abdomen with high-pitched bowel sounds are classic for MBO.
2
Evaluate the patient's goals of care and constraints.
The patient is on home hospice care with strict comfort goals and a documented refusal of surgery, hospital transfer, or nasogastric (NG) tube placement.
Management must align with the patient's values, meaning symptom control must be achieved using non-invasive, home-based pharmacological therapies rather than mechanical decompression.
3
Select the appropriate targeted pharmacologic intervention.
Subcutaneous octreotide is selected to manage the MBO.
Because an NG tube is refused, GI secretions must be reduced pharmacologically. Octreotide inhibits GI secretions and reduces splanchnic blood flow, effectively alleviating the distension, colicky pain, and vomiting associated with MBO.

Key Concept

Pharmacologic management of malignant bowel obstruction in hospice care
Question 4047Question →

Match each clinical scenario or calculation description to the appropriate measure of association or impact.

Click a left item, then click its matching right item

Items

A study enrolls healthy volunteers and categorizes them by daily sodium intake over ten years, ultimately dividing the incidence of hypertension in the high-sodium group by the incidence in the low-sodium group.
Investigators identify patients with and without a specific foodborne illness, then mathematically compare the frequency of suspected restaurant exposure between the two groups.
A clinical trial evaluates a novel statin versus placebo, with researchers calculating the reciprocal of the absolute reduction in myocardial infarction incidence.
A surveillance analysis compares a new antiarrhythmic to a standard beta-blocker by subtracting the adverse event rate of the standard therapy from that of the new drug.

Matches

Show answer & explanation

Answer

The correct matches align cohort incidence ratios with Relative Risk, case-control exposure comparisons with Odds Ratio, the reciprocal of ARR with Number Needed to Treat, and adverse event rate differences with Absolute Risk Increase.
Each study design and mathematical approach inherently aligns with a specific biostatistical measure. Cohort studies utilizing true incidence ratios calculate Relative Risk. Case-control studies comparing exposure frequencies must calculate Odds Ratios. Taking the reciprocal of absolute reduction yields the Number Needed to Treat. Finally, the absolute mathematical difference in harm rates represents the Absolute Risk Increase.

Step-by-Step Solution

1
Identify the study design and mathematical operation described in the first scenario.
The scenario describes dividing the incidence in an exposed group by an unexposed group in a cohort study, which mathematically defines Relative Risk.
Incidence ratios are the defining characteristic of relative risk calculations in observational cohort studies.
2
Analyze the study design based on disease status in the second scenario.
Starting with diseased and non-diseased individuals and comparing past exposures characterizes a case-control study, which utilizes the Odds Ratio.
Case-control studies cannot establish true incidence; therefore, they rely on the odds of exposure to estimate the association.
3
Determine the metric derived from the reciprocal of absolute risk reduction in the third scenario.
The formula 1/ARR1 / ARR specifically calculates the Number Needed to Treat (NNT).
NNT translates the absolute risk reduction into a clinically actionable number of patients needed to prevent one event.
4
Identify the metric representing the simple difference in adverse event rates in the fourth scenario.
Subtracting the standard event rate from a higher new event rate yields the Absolute Risk Increase (ARI).
ARI quantifies the absolute excess risk of harm attributable to a specific exposure or intervention.

Key Concept

Measures of Association and Impact
Question 4048Question →

A 48-year-old man presents to the outpatient clinic to discuss the results of a recent excisional biopsy of a suspicious pigmented skin lesion. The pathology report confirms invasive malignant melanoma with positive margins. The physician prepares to deliver this diagnosis to the patient.

Arrange the following physician statements in the most appropriate chronological sequence for delivering this diagnosis, according to the standard consensus protocol for breaking bad news.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence follows the SPIKES protocol: Setting up the interview, assessing Perception, obtaining an Invitation, giving Knowledge, and addressing Emotions.
The SPIKES protocol is a six-step framework for delivering bad news in clinical practice, designed to minimize patient distress and ensure clear communication. The chronological sequence begins with Setting up the interview (ensuring privacy and support), followed by assessing the patient's Perception (what they already know). The physician then obtains an Invitation (how much information they want) before giving the Knowledge (the diagnosis itself). Immediately following the disclosure, the physician must address Emotions with empathic responses before proceeding to Strategy and Summary (next steps).

Step-by-Step Solution

1
Identify the communication framework being tested by the scenario.
The scenario requires the application of the SPIKES protocol for delivering bad news.
SPIKES is the gold-standard, evidence-based communication strategy for breaking bad news in medical practice.
2
Determine the initial preparatory and assessment statements.
The physician must first involve support systems (Setting) and then determine what the patient already suspects (Perception).
This establishes a safe environment and a baseline understanding before giving new facts.
3
Identify the transitional and informational statements.
The physician asks how much detail the patient wishes to receive (Invitation), followed by the direct delivery of the diagnosis with a warning shot (Knowledge).
This respects patient autonomy regarding information processing and delivers the facts clearly without premature reassurance.
4
Identify the immediate follow-up response.
The physician must respond to the patient's immediate reaction with empathy (Emotion) before moving to any treatment strategy.
Validating the patient's feelings is crucial to prevent overwhelming them with medical plans while they are in emotional shock.

Key Concept

The application of the SPIKES protocol for delivering bad news.
Question 4049Question →

A 6565-year-old man with symptomatic heart failure with reduced ejection fraction (LVEF 30%30\%) is evaluated in the clinic. He is currently taking lisinopril, metoprolol succinate, and spironolactone. His blood pressure is 118/75118/75 mmHg, and his heart rate is 6868/min. A basic metabolic panel shows a serum potassium of 4.64.6 mEq/L and a serum creatinine of 1.21.2 mg/dL. To further optimize his guideline-directed medical therapy, the physician decides to replace lisinopril with sacubitril-valsartan.

Which of the following are required steps in the execution and monitoring of this treatment transition? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Enforce a 3636-hour washout period after the final dose of lisinopril before administering the first dose of sacubitril-valsartan; Reassess serum potassium and renal function with a basic metabolic panel 11 to 22 weeks after initiating sacubitril-valsartan

Answer

The required steps are enforcing a 36-hour washout period after the final lisinopril dose before starting sacubitril-valsartan, and reassessing serum potassium and renal function 1 to 2 weeks after initiation.
Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) that improves morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Neprilysin normally degrades vasoactive peptides, including bradykinin. Because ACE inhibitors (like lisinopril) also inhibit bradykinin breakdown, the concurrent use of an ACE inhibitor and an ARNI significantly increases the risk of life-threatening angioedema. Therefore, a strict 3636-hour washout period is mandatory when transitioning from an ACE inhibitor to an ARNI. (Note: this washout is not required when transitioning from an ARB to an ARNI). Additionally, ARNIs can cause renal impairment and hyperkalemia. Because this patient is concurrently taking spironolactone (a potassium-sparing mineralocorticoid receptor antagonist), reassessing serum creatinine and potassium 11 to 22 weeks after initiation is a necessary monitoring step to prevent severe hyperkalemia or acute kidney injury.

Step-by-Step Solution

1
Analyze the patient's current medication regimen and the planned transition.
The patient is transitioning from an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI, sacubitril-valsartan).
Identifying the specific drug classes is essential for determining washout protocols and necessary monitoring.
2
Determine the washout requirements between an ACE inhibitor and an ARNI.
A strict 36-hour washout period is required.
Both ACE inhibitors and neprilysin inhibitors prevent the breakdown of bradykinin. Overlapping these medications drastically increases the risk of life-threatening angioedema.
3
Identify necessary laboratory monitoring based on the new regimen and concurrent medications.
A basic metabolic panel must be checked in 1 to 2 weeks.
ARNIs can decrease renal perfusion and increase potassium retention. This risk is compounded by the patient's concurrent use of spironolactone (a potassium-sparing diuretic).
4
Evaluate the distractors regarding biomarker monitoring and concurrent therapies.
BNP cannot be used for monitoring, and concurrent GDMT (spironolactone and metoprolol) must be continued.
Neprilysin degrades BNP, so sacubitril falsely elevates BNP levels (NT-proBNP should be used instead). Furthermore, stopping beta-blockers or MRAs inappropriately removes established mortality benefits.

Key Concept

Monitoring and transitioning protocols for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure
Estimated Time:2m 0s
Question 4050Question →

An investigative team is finalizing the protocol for a randomized controlled trial evaluating a novel pharmacologic intervention. During the planning phase, the biostatistics committee reviews several potential modifications to the study design to optimize its validity and efficiency. Match each proposed trial modification with its primary mathematical consequence.

Click a left item, then click its matching right item

Items

Shifting the pre-study significance threshold (α\alpha) from 0.050.05 to 0.010.01 to meet stringent regulatory requirements.
Utilizing a surrogate clinical endpoint that yields a substantially larger expected standardized effect size.
Utilizing a rapid, less precise clinical measurement tool, which introduces greater random error into the primary outcome data.
Dichotomizing the primary continuous outcome variable (e.g., classifying patients strictly as 'responders' or 'non-responders').
Implementing a stratified randomization block design based on the strongest known prognostic demographic factor.

Matches

Show answer & explanation

Answer

The correct matches align each trial design modification with its direct mathematical impact on the study's error rates or statistical power components (numerator effect size, denominator variance, or data structure granularity).
Statistical power is mathematically dependent on the alpha level, effect size, sample variance, and data structure. Modifying these parameters directly alters the formal test statistic. Stratification isolates and removes known variance to increase power, while dichotomizing continuous variables destroys data granularity, causing a severe loss of efficiency.

Step-by-Step Solution

1
Evaluate the impact of shifting the alpha threshold from 0.05 to 0.01.
Matches with: Decreases the probability of falsely rejecting the null hypothesis but simultaneously increases the Type II error rate.
Lowering alpha decreases the chance of a false positive (Type I error) but increases the chance of a false negative (Type II error), thereby lowering power.
2
Evaluate the impact of utilizing an endpoint with a larger effect size.
Matches with: Enhances statistical power by increasing the magnitude of the numerator in the formal test statistic calculation.
In test statistics (like the t-statistic), the difference between means sits in the numerator. A larger effect size increases this numerator, yielding a larger test statistic and higher power.
3
Evaluate the impact of introducing greater random error into the measurement.
Matches with: Reduces statistical power by inflating the denominator (standard error) of the formal test statistic.
Random error adds to the sample variance. Variance dictates the standard error, which is the denominator of the test statistic. A larger denominator yields a smaller test statistic, reducing power.
4
Evaluate the impact of dichotomizing a continuous outcome variable.
Matches with: Leads to a substantial loss of statistical power due to the discarding of continuous data granularity.
Reducing a rich continuous variable (e.g., exact blood pressure) to a binary outcome (e.g., hypertensive vs. normotensive) loses variance data, severely limiting the test's ability to detect true differences.
5
Evaluate the impact of implementing a stratified randomization block design.
Matches with: Increases statistical power by systematically reducing the unexplained residual variance in the outcome measure.
Stratification controls for known prognostic variables, removing their contribution from the 'noise' (residual variance). Less noise means a smaller standard error and therefore greater power.

Key Concept

Hypothesis Testing and Statistical Power
Question 4051Question →

Investigators at a large academic medical center are analyzing data from a recent clinical trial investigating 'Medication Q', an experimental anticoagulant, for the prevention of recurrent deep vein thrombosis (DVT).

The trial included 2,0002,000 high-risk outpatients who were randomly and equally allocated to receive either Medication Q or a placebo. The results after 1212 months of follow-up are summarized below:

OutcomeMedication Q Group (n=1,000n=1,000)Placebo Group (n=1,000n=1,000)
Recurrent DVT3030130130
Major Bleeding Event50501010

Based on the trial data, which of the following statements regarding the statistical impact and clinical interpretation of Medication Q is most accurate?

Show answer & explanation

Answer: Treating 10 patients with Medication Q rather than placebo will prevent one recurrent deep vein thrombosis, whereas treating 25 patients will cause one additional major bleeding event.

Answer

Treating 10 patients with Medication Q rather than placebo will prevent one recurrent deep vein thrombosis, whereas treating 25 patients will cause one additional major bleeding event.
The correct interpretation involves extracting the absolute risk data for both efficacy and safety. The Absolute Risk Reduction (ARR) for DVT is the control risk (13%13\%) minus the treatment risk (3%3\%), which equals 10%10\% (0.100.10). The Number Needed to Treat (NNT) is 1/ARR1 / ARR, yielding 1010. This means 1010 patients must be treated to prevent one DVT. The Absolute Risk Increase (ARI) for major bleeding is the treatment risk (5%5\%) minus the control risk (1%1\%), equating to 4%4\% (0.040.04). The Number Needed to Harm (NNH) is 1/ARI1 / ARI, yielding 2525. Therefore, treating 2525 patients causes one excess major bleeding event.

Step-by-Step Solution

1
Calculate the Absolute Risk Reduction (ARR) for the primary efficacy outcome (Recurrent DVT).
Risk in Placebo = 130 / 1,000 = 0.13. Risk in Medication Q = 30 / 1,000 = 0.03. ARR = 0.13 - 0.03 = 0.10 (10%).
ARR is required to calculate the Number Needed to Treat (NNT).
2
Calculate the Number Needed to Treat (NNT).
NNT = 1 / ARR = 1 / 0.10 = 10.
NNT quantifies how many patients must receive the intervention to prevent one adverse efficacy outcome.
3
Calculate the Absolute Risk Increase (ARI) for the primary safety outcome (Major Bleeding).
Risk in Medication Q = 50 / 1,000 = 0.05. Risk in Placebo = 10 / 1,000 = 0.01. ARI = 0.05 - 0.01 = 0.04 (4%).
ARI is required to calculate the Number Needed to Harm (NNH).
4
Calculate the Number Needed to Harm (NNH).
NNH = 1 / ARI = 1 / 0.04 = 25.
NNH quantifies how many patients must receive the intervention to cause one additional adverse safety outcome.

Key Concept

The Number Needed to Treat (NNT) and Number Needed to Harm (NNH) are derived from the reciprocal of the absolute risk differences between treatment and control groups.
Estimated Time:1m 30s
Question 4052Question →

During a comprehensive health evaluation, a 38-year-old female patient inquires about her cancer risk. She currently feels well and has no physical complaints. Her medical history includes well-controlled asthma, for which she uses an albuterol inhaler as needed. She exercises regularly and follows a balanced diet.

Upon reviewing her family pedigree, the physician notes that her father was diagnosed with breast cancer at age 55, and her paternal grandmother died from ovarian cancer at age 62. Her mother and two younger sisters are alive and healthy. The patient has one child, whom she breastfed for 6 months. A thorough physical examination today, including a detailed clinical breast examination, reveals no palpable masses, skin changes, or axillary lymphadenopathy.

Based on current preventive care guidelines, which of the following is the most appropriate next step in management regarding this patient's cancer risk?

Show answer & explanation

Answer: Referral for formal genetic counseling and consideration of BRCA mutation testing

Answer

The most appropriate next step is referral for formal genetic counseling and consideration of BRCA mutation testing.
This patient's family history includes male breast cancer and ovarian cancer, which are highly characteristic of a BRCA mutation (particularly BRCA2 for male breast cancer). According to the USPSTF guidelines, women with a family history associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes should be referred for genetic counseling and, if indicated, genetic testing. It is a common misconception that paternal family history is less relevant for breast and ovarian cancer risk; however, these mutations are inherited in an autosomal dominant pattern and can be passed through the paternal line. Genetic counseling must precede the initiation of high-risk screening modalities or chemoprevention.

Step-by-Step Solution

1
Analyze the patient's family history for high-risk hereditary cancer patterns.
The patient has a father with male breast cancer and a paternal grandmother with ovarian cancer.
Identifying hereditary cancer syndromes is crucial for implementing appropriate high-risk screening and prevention protocols.
2
Apply USPSTF guidelines for BRCA-related cancer risk assessment.
A family history of male breast cancer and ovarian cancer, even on the paternal side, strongly suggests a BRCA1 or BRCA2 mutation.
USPSTF recommends that primary care clinicians assess women with a family history suggestive of BRCA mutations and refer them for formal genetic counseling.
3
Evaluate the distractor options against standard test sequencing principles.
MRI, tamoxifen, and routine mammography at age 40 are inappropriate initial steps. TVUS and CA-125 are explicitly not recommended for ovarian cancer screening.
Proper test sequencing dictates that genetic risk must be formally established via counseling before initiating high-risk imaging or chemopreventive medications.

Key Concept

Women with a family history indicative of a potential BRCA mutation (including paternal history of breast/ovarian cancer or any male breast cancer) should be referred for formal genetic counseling before initiating high-risk screening or chemoprevention.
Question 4053Question →

Match each patient's clinical presentation with the most appropriate next step in preventive care according to current guidelines.

Click a left item, then click its matching right item

Items

A 71-year-old man who reports a history of smoking 3 to 4 cigarettes daily for about three years in his early twenties, but has abstained since. He takes amlodipine for well-controlled hypertension.
A 35-year-old woman who feels well and has no breast masses. Her mother was diagnosed with breast cancer at age 46, and her maternal aunt had ovarian cancer at age 52.
A 69-year-old man with type 2 diabetes mellitus who received a single dose of the 15-valent pneumococcal conjugate vaccine (PCV15) exactly 12 months ago.
A 22-year-old man who has sex with men, reports inconsistent condom use with multiple recent partners, and had a negative fourth-generation HIV test last week.

Matches

Show answer & explanation

Answer

The 71-year-old former light smoker matches with one-time abdominal aortic aneurysm screening; the 35-year-old woman with a strong family history matches with genetic counseling; the 69-year-old man who received PCV15 last year matches with PPSV23 administration; and the 22-year-old man with high-risk sexual behavior matches with HIV pre-exposure prophylaxis.
Each pairing directly applies current USPSTF and ACIP guidelines by correctly identifying the subtle triggers for screening or prophylaxis. The 71-year-old man meets the >100 lifetime cigarettes threshold for AAA screening. The 35-year-old woman's pedigree triggers BRCA risk assessment. The 69-year-old man completes his pneumococcal series with PPSV23 exactly one year after PCV15. The 22-year-old man's high-risk behavior combined with a negative HIV test warrants PrEP.

Step-by-Step Solution

1
Evaluate the 71-year-old man's smoking history against vascular screening criteria.
He has smoked far more than 100 lifetime cigarettes, classifying him as an 'ever smoker'.
This qualifies him for the USPSTF Grade B recommendation for a one-time abdominal aortic aneurysm ultrasound screening for men aged 65-75, correcting the misconception that heavy pack-years are required for AAA screening.
2
Assess the 35-year-old woman's family oncology pedigree.
She has multiple relatives with BRCA-associated cancers (breast before age 50, ovarian cancer).
This triggers the USPSTF Grade B recommendation for administering a familial risk assessment tool and referring for genetic counseling.
3
Review the 69-year-old man's immunization timeline.
He received PCV15 exactly 12 months ago.
ACIP guidelines dictate that patients who receive PCV15 must be followed up with a dose of PPSV23 at least one year later.
4
Analyze the 22-year-old man's infectious disease risk profile.
He has high-risk sexual exposures and a recently confirmed negative HIV test.
He clearly meets criteria for initiating daily oral pre-exposure prophylaxis (PrEP).

Key Concept

Age- and risk-appropriate preventive care interventions require careful application of specific numeric thresholds (e.g., >100 lifetime cigarettes for AAA screening) and sequential timelines (e.g., PCV15 followed by PPSV23 at 1 year).
Estimated Time:1m 30s
Question 4054Question →

A 66-year-old man presents to the clinic for a follow-up visit. Three weeks ago, he was diagnosed with a left lower extremity unprovoked deep vein thrombosis. He was initially treated with low-molecular-weight heparin and subsequently transitioned to oral warfarin. Today, his international normalized ratio (INR) is subtherapeutic at 1.3. When asked about his medication adherence, the patient states, "I have been skipping doses because my leg feels perfectly fine, and I read online that blood thinners are basically rat poison. Instead, I am taking a high-dose ginseng extract and a vitamin K-rich multivitamin to dissolve the clot naturally." Furthermore, he insists on canceling his screening colonoscopy scheduled for next week, stating he refuses any procedure requiring sedation. His wife, who is present, is highly distressed and demands that the physician immediately declare him legally unfit to make medical decisions due to his dangerous nonadherence. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Ask the patient to describe his understanding of the potential complications of an inadequately treated blood clot.

Answer

The most appropriate next step is to explore the patient's understanding of the risks associated with an untreated deep vein thrombosis by asking him to describe the potential complications.
The correct answer is to ask the patient to describe his understanding of the potential complications of an inadequately treated blood clot. In a patient demonstrating severe nonadherence due to health misconceptions, the foundational step in health education and counseling is to explore the patient's illness perception and baseline knowledge. This approach, often part of the 'Ask-Tell-Ask' or 'Elicit-Provide-Elicit' framework, allows the physician to identify specific health literacy deficits before attempting to correct them. Furthermore, assessing the patient's understanding of the risks of refusing treatment is clinically required to determine his decision-making capacity. Premature reassurance, compromising with contraindicated therapies, or immediately deferring to legal authorities bypasses the essential physician-patient communication needed in this scenario.

Step-by-Step Solution

1
Identify the multiple clinical and ethical challenges presented in the vignette.
The patient exhibits warfarin nonadherence, use of interacting supplements (ginseng and vitamin K), refusal of a colonoscopy, and the wife is demanding a declaration of incompetence.
Establishing all conflicting priorities is necessary to determine the safest and most effective initial intervention.
2
Evaluate the primary objective of health education in a nonadherent patient expressing significant health misconceptions.
The initial step must be to assess the patient's baseline knowledge, health literacy, and illness perception.
Using the 'Elicit-Provide-Elicit' framework prevents paternalistic lecturing and helps the physician determine if the patient actually understands the consequences of his actions.
3
Select the option that appropriately initiates this counseling framework while avoiding clinical and ethical pitfalls.
Asking the patient to describe his understanding of the complications addresses the core communication requirement.
It directly targets the root cause of the nonadherence without prematurely declaring incompetence, ignoring drug interactions, or misapplying preventive guidelines.

Key Concept

In patients exhibiting nonadherence due to health misconceptions, the initial step in patient counseling is to assess their baseline understanding and illness perception to guide targeted health education and evaluate decision-making capacity.
Estimated Time:1m 30s
Question 4055Question →

Investigators at an academic medical center are designing a clinical study to evaluate a novel sublingual medication for the management of chronic, stable angina. The primary endpoint is the reduction in weekly angina episodes over a 4-week observation period. The research team is concerned that baseline differences in coronary anatomy, physical conditioning, and lifestyle habits will introduce significant between-subject variability, potentially masking the drug's true effect. To maximize statistical power and completely eliminate this between-subject confounding, the investigators require a design where each participant serves as their own control. Which of the following is the most appropriate study design for this investigation?

Show answer & explanation

Answer: Crossover randomized trial

Answer

Crossover randomized trial
The correct answer is the crossover randomized trial. In this study design, each participant is randomly assigned to a sequence of treatments. For example, a patient may receive the active drug for 4 weeks, undergo a washout period to allow the drug to leave their system, and then receive the placebo for 4 weeks. Because the exact same individual provides data for both the active and control phases, differences related to genetics, anatomy, and lifestyle (between-subject variability) are perfectly controlled. This design is highly efficient and requires a smaller sample size, but it is strictly limited to chronic, stable conditions (like stable angina or asthma) where the underlying baseline disease does not rapidly progress or cure itself between periods.

Step-by-Step Solution

1
Identify the primary objective and constraints of the investigators.
They want to evaluate a new treatment while completely eliminating between-subject variability by having patients serve as their own controls.
Understanding the methodological requirement (self-control) points directly to specific experimental designs.
2
Evaluate the clinical context of the condition being studied.
The condition is chronic, stable angina, which is a predictable, ongoing disease rather than an acute, curable illness.
Certain study designs require a return to baseline (washout). This is only possible in chronic, stable conditions.
3
Match the methodological requirement to the correct study design.
A crossover trial gives patients Treatment A, followed by a washout period, followed by Treatment B. This sequence ensures every participant acts as their own control.
This is the classic and optimal design for maximizing power and eliminating interpersonal confounding in stable chronic diseases.

Key Concept

Crossover study design
Question 4056Question →

Match each clinical scenario with the most appropriate disposition and care setting.

Click a left item, then click its matching right item

Items

75-year-old with community-acquired pneumonia, confusion, BUN 28 mg/dL, respiratory rate 32/min, and blood pressure 85/50 mmHg
82-year-old, post-operative day 5 for hip fracture repair, medically stable, requires maximum assistance for transfers, can tolerate only 45 minutes of physical therapy daily
62-year-old, post-stroke, medically stable with dense hemiparesis, capable of participating in 3 hours of intensive combined therapy daily
55-year-old with acute unprovoked deep vein thrombosis, normal vital signs, normal renal function, stable home environment

Matches

Show answer & explanation

Answer

The pneumonia patient matches to ICU admission; the hip fracture patient matches to SNF transfer; the stroke patient matches to IRF transfer; and the DVT patient matches to home discharge.
Each patient's clinical stability and functional capacity directly dictates their required care setting: CURB-65 of 4 mandates ICU; ability to tolerate 3 hours of therapy qualifies for IRF; inability to tolerate intense therapy despite needing rehabilitation directs to SNF; and stable DVT is standardly managed as an outpatient.

Step-by-Step Solution

1
Evaluate the clinical severity of acute medical conditions to determine the appropriate acuity level.
The pneumonia patient's CURB-65 score of 4 dictates ICU-level care. The DVT patient is hemodynamically stable with no high-risk features, allowing for safe outpatient management.
Risk stratification tools like CURB-65 guide the decision between critical care, standard inpatient admission, and outpatient management.
2
Assess the functional capacity and therapy tolerance for post-acute care transitions.
The stroke patient can tolerate 3 hours of daily therapy (IRF criteria), while the hip fracture patient can only tolerate 45 minutes (SNF criteria).
Regulatory and clinical criteria strictly differentiate post-acute care settings based on the intensity of rehabilitation the patient can actively participate in.

Key Concept

Appropriate disposition requires synthesizing objective clinical severity scores (e.g., CURB-65) with functional status, primarily a patient's ability to tolerate specific therapy durations.
Question 4057Question →

An occupational health clinic evaluates a prospective employee who is completing his onboarding physical. The patient is 4141 years of age and reports a history of mild intermittent asthma, for which he uses an albuterol inhaler occasionally. He weighs 105105 kg (231231 lbs) and is 178178 cm (55 ft 1010 in) tall, giving him a body mass index (BMI) of 3333 kg/m 2^2. He currently smokes 11 pack of cigarettes per day and has done so since age 1919. He states he has not undergone any medical evaluations or received any vaccinations since high school. Which of the following preventive health interventions are definitively indicated for this patient at today's visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Administration of the 20-valent pneumococcal conjugate vaccine (PCV20); Screening for type 2 diabetes mellitus with a fasting plasma glucose or hemoglobin A1c

Answer

The indicated interventions are administration of the pneumococcal conjugate vaccine and screening for type 2 diabetes mellitus.
The correct interventions are based on combining the patient's risk factors with current guidelines. First, the patient is 41 years old and has a BMI of 33 kg/m^2 (obesity). The USPSTF recommends screening for type 2 diabetes in adults aged 35 to 70 years who are overweight or obese. Second, the patient has mild intermittent asthma and is a current smoker. The CDC's ACIP recommends pneumococcal vaccination (such as PCV20) for adults aged 19 to 64 years who have chronic medical conditions (including asthma) or who are cigarette smokers. Both of these interventions are strongly indicated at this visit.

Step-by-Step Solution

1
Evaluate the patient's age and BMI for metabolic screening indications.
The patient is 41 years old with a BMI of 33 kg/m^2.
USPSTF guidelines recommend diabetes screening for overweight or obese adults starting at age 35.
2
Assess the patient's medical history and social history for immunization indications.
The patient has asthma and is a current smoker.
ACIP guidelines recommend pneumococcal vaccination for adults aged 19 to 64 years with asthma or a history of smoking.
3
Determine if the patient meets age cutoffs for lung, colon, or vascular screening based on his smoking history and age.
The patient is 41, which is below the threshold for LDCT (age 50), colon cancer screening (age 45), and AAA screening (age 65).
Applying age-specific parameters prevents unnecessary testing and resource overutilization.

Key Concept

Application of age- and risk-based preventive screening and immunization guidelines for adults.
Question 4058Question →

A pharmaceutical company is developing a novel Janus kinase (JAK) inhibitor for the treatment of severe, refractory rheumatoid arthritis. Regulatory guidelines stipulate that the manufacturer must conduct two independent, pivotal Phase III randomized controlled trials demonstrating efficacy. The research team designs Trial X with a statistical power of 80% and Trial Y with a statistical power of 90% to detect the predefined minimum clinically important difference. Both trials use a two-sided alpha level of 0.05.

Assuming the new JAK inhibitor is genuinely effective at or above the minimum clinically important difference, what is the probability (expressed as a percentage) that BOTH trials will fail to yield statistically significant results?

Show answer & explanation

Answer: 2

Answer

2
Statistical power (1−β1 - \beta) is the probability of correctly rejecting the null hypothesis when a true effect exists. A Type II error (β\beta) occurs when a study fails to detect a true effect, resulting in a false negative. The probability of Trial X failing is its Type II error rate: βX=1−0.80=0.20\beta_X = 1 - 0.80 = 0.20. The probability of Trial Y failing is βY=1−0.90=0.10\beta_Y = 1 - 0.90 = 0.10. Because the two pivotal trials are designed to be independent, the joint probability of both trials simultaneously failing to detect the true effect is the product of their individual Type II error rates: 0.20×0.10=0.020.20 \times 0.10 = 0.02. Expressed as a percentage, this is 2%.

Step-by-Step Solution

1
Define statistical power and Type II error
Power = 1−β1 - \beta, so β\beta (Type II error rate) = 1−Power1 - \text{Power}
To find the probability of a trial failing to detect a true effect, we must calculate its Type II error rate.
2
Calculate Type II error for each trial
Trial X β=1−0.80=0.20\beta = 1 - 0.80 = 0.20; Trial Y β=1−0.90=0.10\beta = 1 - 0.90 = 0.10
Each trial has an independent probability of failing to achieve statistical significance despite a true underlying effect.
3
Calculate joint probability
Joint probability = 0.20×0.10=0.020.20 \times 0.10 = 0.02
The probability of multiple independent events all occurring is the product of their individual probabilities.
4
Convert to percentage
0.02×100=2%0.02 \times 100 = 2\%
The question specifically asks for the probability expressed as a percentage.

Key Concept

The probability of failing to detect a true difference in a study is the Type II error rate (β\beta), calculated as 1−Power1 - \text{Power}. The probability of independent trials both making a Type II error is the product of their individual β\beta values.
Question 4059Question →

Match each end-of-life clinical scenario or surrogate decision-making context with the corresponding ethical standard or advance care planning tool.

Click a left item, then click its matching right item

Items

A surrogate decision-maker refuses a feeding tube for an incapacitated patient, stating, 'He explicitly told me last year he never wanted artificial nutrition or machines keeping him alive.'
A court-appointed guardian consents to a palliative surgical procedure for an adult who has had profound intellectual disability since birth, aiming to relieve suffering.
A competent patient completes a legal document specifying their desire to refuse mechanical ventilation and artificial feeding if they ever enter a persistent vegetative state.
An active medical order set, signed by a clinician, that travels with a home hospice patient to direct emergency medical services regarding CPR and intubation in the community.

Matches

Show answer & explanation

Answer

The correct matches align surrogate decisions based on prior wishes to the Substituted judgment standard, decisions for those without prior capacity to the Best interest standard, future hypothetical care legal documents to a Living will, and actionable emergency medical orders to a POLST.
Each matching pair correctly identifies the distinct ethical framework or legal instrument utilized in end-of-life and palliative care decision-making. The substituted judgment standard applies when prior wishes are known; the best interest standard applies when they are not. A living will guides future care, while a POLST dictates immediate emergency response.

Step-by-Step Solution

1
Evaluate the foundation of the surrogate's decision-making in the first two clinical scenarios.
Determine that decisions relying on known prior values utilize the substituted judgment standard, whereas decisions for individuals who never had capacity utilize the best interest standard.
Ethical frameworks dictate distinct standards for surrogates depending on the patient's historical capacity and previously expressed wishes.
2
Differentiate between the end-of-life planning documents provided in the latter two scenarios.
Identify that a legal document anticipating future states is a Living will, whereas a portable medical order for immediate execution by emergency personnel is a POLST.
Clinical applicability changes entirely based on whether a document provides general future guidance (requiring interpretation) or immediate, actionable medical orders.

Key Concept

Ethical Standards and Advance Care Planning at the End of Life
Question 4060Question →

A 48-year-old man comes to the emergency department reporting four days of fever, chills, and a cough productive of yellowish sputum. He has no significant past medical history and takes no daily medications. Vital signs are temperature 38.1°C (100.6°F), blood pressure 122/78 mm Hg, pulse 92/min, and respiratory rate 16/min. Pulse oximetry shows 97% on room air. Physical examination reveals bronchial breath sounds and crackles over the left lower lung field. Laboratory testing shows a leukocyte count of 11,200/mm³ and a blood urea nitrogen of 14 mg/dL. Chest radiography confirms a left lower lobe consolidation consistent with community-acquired pneumonia. The physician determines the patient is at low medical risk and is clinically appropriate for oral antibiotic therapy. However, upon discussing discharge planning, the patient states he was evicted two weeks ago, is currently sleeping in his vehicle, has no health insurance, and possesses only a few dollars. Which of the following is the most appropriate disposition plan for this patient?

Show answer & explanation

Answer: Consult social services to dispense oral antibiotics prior to discharge and arrange recuperative shelter care

Answer

Consult social services to dispense oral antibiotics prior to discharge and arrange for recuperative shelter care.
This patient has community-acquired pneumonia (CAP) with a CURB-65 score of 0 (Confusion: absent, Uremia: BUN <20 mg/dL, Respiratory rate: <30/min, Blood pressure: systolic ≥90 and diastolic ≤60 mm Hg absent, Age: <65 years). A score of 0 signifies a very low 30-day mortality risk, making the patient medically appropriate for outpatient treatment with oral antibiotics. However, disposition requires factoring in both medical stability and the safety of the discharge environment. This patient is experiencing homelessness and extreme poverty, making a standard discharge with a written prescription highly unsafe. He will likely be unable to fill the prescription, leading to treatment failure, clinical deterioration, and readmission. The most appropriate management is to involve social services to ensure the patient receives the medication in hand prior to leaving the ED, and to arrange for medical respite care (recuperative care). Respite care provides temporary room, board, and basic oversight for individuals experiencing homelessness who are too well for the hospital but too sick to safely recover on the streets.

Step-by-Step Solution

1
Assess the medical severity of the patient's community-acquired pneumonia.
The patient is young, has normal vital signs (other than mild fever), and normal BUN. His CURB-65 score is 0, indicating he is medically safe for outpatient oral antibiotic therapy.
Risk stratification scores like CURB-65 or PSI dictate the appropriate clinical level of care (inpatient vs. outpatient).
2
Identify barriers to a safe discharge based on the patient's social history.
The patient is homeless, uninsured, and lacks funds, meaning he cannot purchase prescribed medications or recover in a safe environment.
Social determinants of health heavily influence disposition planning and can override medical risk scores if a safe discharge cannot be guaranteed.
3
Select a disposition that matches both medical needs and social realities.
Medical respite care (recuperative shelter care) with medications in hand is selected.
It prevents unnecessary acute hospitalization while ensuring the patient receives the required treatment and a safe environment for recovery.

Key Concept

Patients who are medically stable for discharge but lack safe housing or resources should be transitioned to medical respite care (recuperative care) with medications provided, avoiding both unsafe community discharge and unnecessary acute hospitalization.
PreviousPage 203 / 237Next
All practice questions — USMLE Step 3 | Examkin